/ Press Release Details /

Genitourinary therapeutics market Size Worth $30.2 Billion By 2025 | CAGR: 1.2%

The global genitourinary therapeutics market is expected to grow at growth rate of 1.2% to reach USD 30.2 billion by 2025. The continuous increase in the prevalence of genitourinary disorders across the globe stimulates the market growth significantly. In addition, rising research and development activities coupled with a vast array of pipeline drugs with a high probability of regulatory approval is anticipated to be a high impact growth rendering driver for this industry. However, patient expiry and the influx of generic therapeutics pull back the industry growth to some extent. Companies namely GlaxoSmithKline, Bayer, Abbott, Roche, and Novartis are actively operating in this market. The industry is characterized by the presence of multinational companies as well as the presence of small players is noticeable too. For instance, in February 2017, Argos Therapeutics participated in 2017 Genitourinary Cancers Symposium cosponsored by the American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and Society of Urologic Oncology (SUO). The company aimed to present its product offering among the investors through such participation.

Key Takeaways:

Of the different indications, prostate cancer constitutes the largest share. In 2017, this segment has recorded USD 7.38 billion revenue i.e. over 25% share of the total market
Availability of wide range of effective therapeutics such as radiopharmaceuticals, anti-neoplastic agents and immunotherapy that can impede disease progression and heightened survival chances, support the segment growth.
Furthermore, the introduction of advanced formulation techniques by key players’ drive the prostate cancer segment to great extent. For instance, the launch of Xofigo (Radium-223) to treat advanced prostate cancer.
Renal cancer is considered to be the second largest revenue generating segment owing to the increasing incidences of this disease. According to the World Health Organization (WHO), urinary tract infection is the leading cause of morbidity and healthcare expenditure in patients of all age groups.
Genitourinary conditions such as interstitial cystitis and bladder cancer are projected to grow with a lucrative CAGR over the forecast period
Based on products, urological and hormonal therapy captured the highest revenue share due to its high efficiency and cost-effectiveness. In 2017, these segments accounted for more than 50% revenue share collectively.
Additionally, strong demand for these segment is backed by growing demand for therapeutics such as Edex(Urological), Myrbetriq (Urological), Lupron(Hormonal drug), Xtandi(Hormonal drug) and Zytiga(Hormonal drug)
Regionally, North America dominated the global industry with 42.6% share in 2017. Increasing prevalence of genitourinary diseases coupled with favorable government initiatives augments the regional development.

KEY BENEFITS OF THE REPORT:

The report presents macro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
Thorough analysis of relevant statistical data to estimate the market paradigms
Exceptional understanding of region and country specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

The scope of this report covers the market by its major segments, which include as follows:

Market Segmentation

MARKET, BY INDICATION